Halozyme Therapeutics, Inc. (LON:0J2O)
London · Delayed Price · Currency is GBP · Price in USD 76.32
-0.71 (-0.92%)
At close: Sep 15, 2025
Halozyme Therapeutics Market Cap
Halozyme Therapeutics has a market cap or net worth of 6.49 billion as of September 18, 2025. Its market cap has increased by 5.45% in one year.
Market Cap
6.49B
Enterprise Value
7.21B
Revenue
860.31M
Ranking
n/a
PE Ratio
15.96
Stock Price
76.32
Market Cap Chart
Since May 14, 2004, Halozyme Therapeutics's market cap has increased from 95.57M to 6.49B, an increase of 6,691.21%. That is a compound annual growth rate of 21.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2025 | 6.49B | 33.58% |
| Dec 31, 2024 | 4.86B | 26.76% |
| Dec 29, 2023 | 3.83B | -39.97% |
| Dec 30, 2022 | 6.39B | 52.80% |
| Dec 31, 2021 | 4.18B | -1.03% |
| Dec 31, 2020 | 4.22B | 115.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 175.94B |
| GSK plc | 58.89B |
| Haleon | 30.40B |
| Smith & Nephew | 11.94B |
| ConvaTec Group | 4.69B |
| Hikma Pharmaceuticals | 3.58B |
| HUTCHMED (China) | 2.12B |
| Genus | 1.65B |